Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Metformin Therapy and Breast Cancer Incidence in the Hail Region

Mhdia Osman
* ORCID logo ,
Taif Muqbel
,
Ahad Alenzi
,
Shuruq Alenzi
,
Nasrin Kalifa
ORCID logo ,
Weam Khojali
,
Halima Mustafa Elagib
Version 1 : Received: 11 December 2022 / Approved: 14 December 2022 / Online: 14 December 2022 (03:33:08 CET)
Version 2 : Received: 1 January 2023 / Approved: 13 January 2023 / Online: 13 January 2023 (07:29:32 CET)

How to cite: Osman, M.; Muqbel, T.; Alenzi, A.; Alenzi, S.; Kalifa, N.; Khojali, W.; Elagib, H.M. Metformin Therapy and Breast Cancer Incidence in the Hail Region. Preprints 2022, 2022120244. https://doi.org/10.20944/preprints202212.0244.v1 Osman, M.; Muqbel, T.; Alenzi, A.; Alenzi, S.; Kalifa, N.; Khojali, W.; Elagib, H.M. Metformin Therapy and Breast Cancer Incidence in the Hail Region. Preprints 2022, 2022120244. https://doi.org/10.20944/preprints202212.0244.v1

Abstract

Metformin is a drug used to treat patients with type 2 diabetes, especially those who suffer from obesity. It is also used in treating women with polycystic ovary syndrome (PCOS). This disease has been shown to be related to insulin resistance and multiplied blood sugar ranges. Further, it has been found that using metformin improves these women's menstrual cycles and ovulation rates. Methods: A structured questionnaire will be conducted to determine the prevalence of breast cancer among women using metformin in the Hail region. Result: The incidence of breast cancer among women using metformin in the Hail region is very low. Conclusions: According to previous findings, metformin has been linked to lower breast cancer risk in women with type 2 diabetes. Furthermore, the findings of this study have corroborated the literature for the same by indicating a substantial connection between metformin use and a lower risk of breast cancer in women with type 2 diabetes.

Keywords

breast cancer; diabetes; metformin

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (2)

Comment 1
Received: 14 December 2022
Commenter:
Weiam Abdulrahim Abdulqadir Hussien

The commenter has declared there is no conflict of interests.
Comment: This is an interesting study and the authors have collected a unique dataset using reliable methodology. The paper is generally well written and structured. However, I suggested to cite extra and recent literature.
+ Respond to this comment
Response 1 to Comment 1
Received: 11 January 2023
Commenter:
Mhdia Elhadi Dafa Alla Osman

The commenter has declared there is no conflict of interests.
Comment: We appreciate the reviewer for your valuable and constructive comments. We really thank the reviewer for kind and critical comments.
references No. 12, 13 were added

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 2
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.